Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 457

1.

Recent advances in understanding and managing Paget's disease.

Reid IR.

F1000Res. 2019 Aug 22;8. pii: F1000 Faculty Rev-1485. doi: 10.12688/f1000research.19676.1. eCollection 2019. Review.

2.

Bisphosphonates for Prevention of Bone Loss in Glucocorticoid-Treated Young People.

Reid IR.

EClinicalMedicine. 2019 Jul 12;12:8-9. doi: 10.1016/j.eclinm.2019.07.002. eCollection 2019 Jul. No abstract available.

3.

Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells.

Park YE, Bava U, Lin JM, Cornish J, Naot D, Reid IR.

Calcif Tissue Int. 2019 Jul 19. doi: 10.1007/s00223-019-00590-5. [Epub ahead of print]

PMID:
31324954
4.

Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy.

Bolland MJ, Horne AM, Briggs SE, Thomas MG, Reid IR, Gamble GD, Grey A.

Calcif Tissue Int. 2019 Oct;105(4):423-429. doi: 10.1007/s00223-019-00579-0. Epub 2019 Jun 27.

PMID:
31250043
5.

Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up.

Horne AM, Mihov B, Reid IR.

Calcif Tissue Int. 2019 Jul;105(1):107-108. doi: 10.1007/s00223-019-00553-w. Epub 2019 Apr 17. No abstract available.

PMID:
31087124
6.

Fibroblast growth factor 23 levels decline following sleeve gastrectomy.

Billington EO, Murphy R, Gamble GD, Callon K, Davies N, Plank LD, Booth M, Reid IR.

Clin Endocrinol (Oxf). 2019 Jul;91(1):87-93. doi: 10.1111/cen.13981. Epub 2019 Apr 15.

PMID:
30943313
7.

Fracture Prevention with Zoledronate in Older Women with Osteopenia. Reply.

Reid IR, Horne AM, Gamble GD.

N Engl J Med. 2019 Mar 28;380(13):1288. doi: 10.1056/NEJMc1900923. No abstract available.

PMID:
30917270
8.

Dietary Calcium Intake and Bone Loss Over 6 Years in Osteopenic Postmenopausal Women.

Bristow SM, Horne AM, Gamble GD, Mihov B, Stewart A, Reid IR.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3576-3584. doi: 10.1210/jc.2019-00111.

PMID:
30896743
9.

Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wiessing KR, Bolland MJ, Bastin S, Gamble GD.

J Intern Med. 2019 Aug;286(2):221-229. doi: 10.1111/joim.12901. Epub 2019 Apr 8.

PMID:
30887607
10.
11.

Fracture Prevention with Zoledronate in Older Women with Osteopenia.

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD.

N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082. Epub 2018 Oct 1.

PMID:
30575489
12.

High-dose vitamin D: Without benefit but not without risk.

Reid IR.

J Intern Med. 2018 Dec;284(6):694-696. doi: 10.1111/joim.12836. Epub 2018 Oct 14. No abstract available.

PMID:
30230641
13.

Calcium and vitamin D: To supplement or not?

Reid IR.

Cleve Clin J Med. 2018 Sep;85(9):693-698. doi: 10.3949/ccjm.85a.18026. No abstract available.

14.

Effects of Leptin on the Skeleton.

Reid IR, Baldock PA, Cornish J.

Endocr Rev. 2018 Dec 1;39(6):938-959. doi: 10.1210/er.2017-00226. Review.

PMID:
30184053
15.

Calcium and vitamin D do not prevent fractures in community-dwelling adults.

Reid IR.

BMJ Evid Based Med. 2018 Oct;23(5):185-186. doi: 10.1136/bmjebm-2018-110974. Epub 2018 Jun 21. Review. No abstract available.

PMID:
29930018
16.

Denosumab for glucocorticoid-induced osteoporosis.

Reid IR.

Nat Rev Endocrinol. 2018 Jul;14(7):383-384. doi: 10.1038/s41574-018-0035-z. No abstract available.

PMID:
29849116
17.

25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a Randomized Controlled Trial.

Macdonald HM, Reid IR, Gamble GD, Fraser WD, Tang JC, Wood AD.

J Bone Miner Res. 2018 Aug;33(8):1464-1469. doi: 10.1002/jbmr.3442. Epub 2018 Jun 15.

18.

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.

Horne AM, Mihov B, Reid IR.

Calcif Tissue Int. 2018 Jul;103(1):55-61. doi: 10.1007/s00223-018-0404-6. Epub 2018 Feb 14.

PMID:
29445836
19.

Vitamin D Effect on Bone Mineral Density and Fractures.

Reid IR.

Endocrinol Metab Clin North Am. 2017 Dec;46(4):935-945. doi: 10.1016/j.ecl.2017.07.005. Epub 2017 Sep 29. Review.

PMID:
29080644
20.

Lack of Evidence that Soluble Urate Directly Influences Bone Remodelling: A Laboratory and Clinical Study.

Dalbeth N, Pool B, Chhana A, Lin JM, Tay ML, Tan P, Callon KE, Naot D, Horne A, Drake J, Gamble GD, Reid IR, Grey A, Stamp LK, Cornish J.

Calcif Tissue Int. 2018 Jan;102(1):73-84. doi: 10.1007/s00223-017-0328-6. Epub 2017 Oct 10.

PMID:
29018897
21.

Calcium and Cardiovascular Disease.

Reid IR, Birstow SM, Bolland MJ.

Endocrinol Metab (Seoul). 2017 Sep;32(3):339-349. doi: 10.3803/EnM.2017.32.3.339. Review.

22.

Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.

Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR.

CMAJ. 2017 Sep 11;189(36):E1130-E1136. doi: 10.1503/cmaj.161207.

23.

Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial.

Reid IR, Horne AM, Mihov B, Gamble GD, Al-Abuwsi F, Singh M, Taylor L, Fenwick S, Camargo CA, Stewart AW, Scragg R.

J Intern Med. 2017 Nov;282(5):452-460. doi: 10.1111/joim.12651. Epub 2017 Jul 26.

PMID:
28692172
24.

Are more trials of calcium supplements really needed?

Bolland MJ, Grey A, Reid IR.

Osteoporos Int. 2017 Sep;28(9):2729-2730. doi: 10.1007/s00198-017-3988-1. Epub 2017 Jul 7. No abstract available.

PMID:
28687861
25.

Dietary calcium intake and rate of bone loss in men.

Bristow SM, Gamble GD, Horne AM, Reid IR.

Br J Nutr. 2017 May;117(10):1432-1438. doi: 10.1017/S0007114517001301. Epub 2017 Jun 13.

PMID:
28606219
26.

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.

Reid IR.

BioDrugs. 2017 Aug;31(4):289-297. doi: 10.1007/s40259-017-0229-2. Review.

PMID:
28547661
27.

Serum phosphate is related to adiposity in healthy adults.

Billington EO, Gamble GD, Bristow S, Reid IR.

Eur J Clin Invest. 2017 Jul;47(7):486-493. doi: 10.1111/eci.12769. Epub 2017 Jun 13.

PMID:
28517037
28.

Bone Loss After Denosumab: Only Partial Protection with Zoledronate.

Reid IR, Horne AM, Mihov B, Gamble GD.

Calcif Tissue Int. 2017 Oct;101(4):371-374. doi: 10.1007/s00223-017-0288-x. Epub 2017 May 13.

PMID:
28500448
29.

Calcium Intake and Cardiovascular Disease Risk.

Reid IR, Avenell A, Grey A, Bolland MJ.

Ann Intern Med. 2017 May 2;166(9):684-685. doi: 10.7326/L17-0135. No abstract available.

PMID:
28460389
30.

Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.

Reid IR, Maslowski K.

Calcif Tissue Int. 2017 Jul;101(1):43-49. doi: 10.1007/s00223-017-0261-8. Epub 2017 Mar 21.

PMID:
28324123
31.

Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.

Billington EO, Horne A, Gamble GD, Maslowski K, House M, Reid IR.

Osteoporos Int. 2017 Jun;28(6):1867-1874. doi: 10.1007/s00198-017-3960-0. Epub 2017 Feb 23.

PMID:
28233020
32.

Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men.

Billington EO, Gamble GD, Reid IR.

Bonekey Rep. 2016 Dec 7;5:852. doi: 10.1038/bonekey.2016.85. eCollection 2016.

33.

Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.

Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw.

J Clin Densitom. 2017 Jan - Mar;20(1):8-24. doi: 10.1016/j.jocd.2016.09.005. Epub 2016 Dec 9. Review.

PMID:
27956123
34.

Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone.

Reid IR, Wattie D, Gamble GD, Kalluru R, Cundy T.

Calcif Tissue Int. 2017 Mar;100(3):250-254. doi: 10.1007/s00223-016-0214-7. Epub 2016 Nov 19.

PMID:
27866237
35.

Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.

Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, Brown TD, Cheung AM, Cody K, Cooper C, Diez-Perez A, Eastell R, Hadji P, Hosoi T, Jan De Beur S, Kagan R, Kiel DP, Reid IR, Solomon DH, Randall S.

J Bone Miner Res. 2017 Jan;32(1):3-10. doi: 10.1002/jbmr.3039. Epub 2016 Dec 27.

36.

Durability of Response to Zoledronate Treatment and Competing Mortality in Paget's Disease of Bone.

Cundy T, Maslowski K, Grey A, Reid IR.

J Bone Miner Res. 2017 Apr;32(4):753-756. doi: 10.1002/jbmr.3029. Epub 2016 Nov 30.

37.

Postmenopausal osteoporosis.

Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR.

Nat Rev Dis Primers. 2016 Sep 29;2:16069. doi: 10.1038/nrdp.2016.69. Review.

PMID:
27681935
38.

Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention.

Avenell A, Bolland MJ, Grey A, Reid IR.

Osteoporos Int. 2017 Feb;28(2):733-734. doi: 10.1007/s00198-016-3765-6. Epub 2016 Sep 19. No abstract available.

PMID:
27647527
39.

Acute effects of calcium supplements on blood pressure: randomised, crossover trial in postmenopausal women.

Billington EO, Bristow SM, Gamble GD, de Kwant JA, Stewart A, Mihov BV, Horne AM, Reid IR.

Osteoporos Int. 2017 Jan;28(1):119-125. doi: 10.1007/s00198-016-3744-y. Epub 2016 Aug 20.

PMID:
27543500
40.

Controversies in osteoporosis management.

Reid IR.

Intern Med J. 2016 Jul;46(7):767-70. doi: 10.1111/imj.13131. No abstract available.

PMID:
27405889
41.

Vitamin D supplements do not prevent falls.

Bolland MJ, Grey A, Reid IR.

BMJ. 2016 Jun 1;353:i3005. doi: 10.1136/bmj.i3005. No abstract available.

PMID:
27250717
42.

Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review.

Reid IR, Sharma S, Kalluru R, Eagleton C.

Calcif Tissue Int. 2016 Sep;99(3):322-5. doi: 10.1007/s00223-016-0150-6. Epub 2016 May 18. Review.

PMID:
27193832
43.

Errors in NOF meta-analyses of calcium and vitamin D supplements.

Bolland MJ, Avenell A, Grey A, Reid IR.

Osteoporos Int. 2016 Aug;27(8):2637-9. doi: 10.1007/s00198-015-3466-6. Epub 2016 Mar 18. No abstract available.

PMID:
26992924
44.

Towards a trial-based definition of vitamin D deficiency.

Reid IR.

Lancet Diabetes Endocrinol. 2016 May;4(5):376-7. doi: 10.1016/S2213-8587(16)00079-6. Epub 2016 Mar 2. No abstract available.

45.

Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.

Rizzoli R, Benhamou CL, Halse J, Miller PD, Reid IR, Rodríguez Portales JA, DaSilva C, Kroon R, Verbruggen N, Leung AT, Gurner D.

Osteoporos Int. 2016 Jun;27(6):2099-107. doi: 10.1007/s00198-016-3503-0. Epub 2016 Feb 15.

PMID:
26879200
46.

Reasons for discrepancies in hip fracture risk estimates using FRAX and Garvan calculators.

Billington EO, Gamble GD, Reid IR.

Maturitas. 2016 Mar;85:11-8. doi: 10.1016/j.maturitas.2015.12.003. Epub 2015 Dec 8.

PMID:
26857874
47.

Calcium fortified foods or supplements for older people?

Reid IR, Bristow SM.

Maturitas. 2016 Mar;85:1-4. doi: 10.1016/j.maturitas.2015.11.012. Epub 2015 Dec 2. No abstract available.

PMID:
26857872
48.

Path Analysis Identifies Receptor Activator of Nuclear Factor-κB Ligand, Osteoprotegerin, and Sclerostin as Potential Mediators of the Tophus-bone Erosion Relationship in Gout.

Chhana A, Aati O, Gamble GD, Callon KE, Doyle AJ, Roger M, McQueen FM, Horne A, Reid IR, Cornish J, Dalbeth N.

J Rheumatol. 2016 Feb;43(2):445-9. doi: 10.3899/jrheum.150738. Epub 2016 Jan 15.

PMID:
26773114
49.

Circulating calcium concentrations, vascular disease and mortality: a systematic review.

Reid IR, Gamble GD, Bolland MJ.

J Intern Med. 2016 Jun;279(6):524-40. doi: 10.1111/joim.12464. Epub 2016 Jan 8. Review.

50.

Relationship Between Changes in Serum Urate and Bone Mineral Density During Treatment with Thiazide Diuretics: Secondary Analysis from a Randomized Controlled Trial.

Dalbeth N, Gamble GD, Horne A, Reid IR.

Calcif Tissue Int. 2016 May;98(5):474-8. doi: 10.1007/s00223-015-0101-7. Epub 2015 Dec 28.

PMID:
26713333

Supplemental Content

Support Center